Ammann NL - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant.

Geidel G, Ammann NL, Schneider SW, Gebhardt C. Geidel G, et al. Among authors: ammann nl. J Dtsch Dermatol Ges. 2021 Jul;19 Suppl 1:37-39. doi: 10.1111/ddg.14480. J Dtsch Dermatol Ges. 2021. PMID: 33835653 No abstract available.

Adjuvant pembrolizumab-related hyperprogression in stage III melanoma.

Ammann NL, Geidel G, Schneider SW, Gebhardt C. Ammann NL, et al. J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535. Epub 2021 Jul 13. J Dtsch Dermatol Ges. 2021. PMID: 34255418 No abstract available.

Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III.

Ammann NL, Geidel G, Schneider SW, Gebhardt C. Ammann NL, et al. J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535_g. J Dtsch Dermatol Ges. 2021. PMID: 34541804 No abstract available.

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma.

Ammann NL, Schwietzer YF, Mess C, Stadler JC, Geidel G, Kött J, Pantel K, Schneider SW, Utikal J, Bauer AT, Gebhardt C. Ammann NL, et al. Cancers (Basel). 2022 Nov 18;14(22):5676. doi: 10.3390/cancers14225676. Cancers (Basel). 2022. PMID: 36428768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4 results

Search Page

Filters